Mono- or combine immunosuppressants are commonly used for psoriasis; however the side effect caused by potent systemic\r\nimmunosuppressants frequently incurred; moreover the inflammation flares up shortly after immunosuppressants are discontinued.\r\nAn alternative nonimmunosuppressive therapy was introduced to psoriasis subjects. A retrospective observational study\r\nconsisted of 1583 psoriasis patients who were treated with Herose Psoria capsule 1440 mg three times daily at two clinical centres,\r\none in China, the other in Singapore, from 1 January 2000 to 1 January 2011. Psoriasis lesion evolution was photographed\r\nat monthly visit, and efficacy and safety were assessed using psoriasis area severity index PASI score grading, renal and liver\r\nfunction testing, and adverse event reporting and supplemented by information obtained during targeted telephone interviews.\r\nThe effectiveness of Herose on psoriasis was inversely associated to prior immunosuppressants exposure (r = 0.9154), significant\r\nimprovements occurred in non-immunosuppressants subjects, and complete clearance was achieved in 8 months (87.5%, 14 of\r\n16); the wavelike evolution of psoriatic lesion appeared in prior immunosuppressants subjects.
Loading....